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     Hepatitis C virus (HCV) is an important agent causing chronic liver infection, which often leads to liver 
cirrhosis and lethal hepatocellular carcinoma (HCC). At present, there is no effective HCV vaccine for 
prevention of hepatic disease and the standard treatment is neither economical nor fully effective in all the 
patients. However, vaccination based on structural and nonstructural proteins of HCV has attracted a special 
interest. Different heterologous systems have been used to generate the recombinant HCV core, E1, and E2 
proteins including Escherichia coli, yeast, insects and mammalian cells. Further studies showed that the 
amounts of HCV recombinant proteins in E. coli are more suitable and un-expensive compared to other 
systems. It should be considered that this system is not efficient for generation of the glycosylated proteins. 
Thus, the structure of proteins is an important agent of selection for expression systems. The selection of 
expression systems will be critical for the use of recombinant proteins as an immunogen. In this mini-
review, we briefly describe different expression systems for generation of the HCV recombinant structural 
proteins applied in vaccine design.  
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INTRODUCTION 
     Hepatitis C virus (HCV) infection is a major 
medical problem both in developed and 
developing countries [1, 4]. HCV is the member 
of the Flaviviridae family and the viral products 
(Core, E1, E2, NS2, NS3, NS4A, NS4B, NS5A, 
and NS5B) are produced from a 3000 amino acid 
polyprotein expressed from a single open reading 
frame [1, 2, 4]. This polyprotein cleaves to 
structural and non-structural proteins using 
cellular and viral protease. The HCV structural 
proteins include the nucleocapsid or core protein 
(29) and the two envelope glycoproteins, E1 and 
E2 [3]. The HCV core protein regulates the 
cellular processes, contributes to viral replication 
and pathogenesis and expresses membrane protein 
features [5]. A tendency to aggregation is a 
characteristic of the HCV glycoproteins, and it 
may be play a key role in virus pathogenesis [3]. 
E1E2 heterodimers also can bind the virus to the 
cell and then enter it [3]. These proteins can 
release neutralizing antibodies against HCV 
infections in the host and thus, core, E1 and E2 
proteins are suggested as the main vaccine 
candidates [4]. The non-structural proteins are 
thought to generate the viral replicase complex 
[5]. The C-terminal component of the polyprotein 
contains non-structural proteins (NS2, NS3, 
NS4A, NS4B, NS5A and NS5B) that provide 
functions necessary for synthesis of viral RNA 
and also assembly of infectious particles [6-8]. 
Recently, improvement of vaccine strategies 
against HCV infections has attracted a special 
interest. Protein vaccination is a major approach 
for prevention of HCV infections [29,30]. One of 
the most important subjects in design of protein 
vaccine is the selection of suitable expression 
systems. Herein, we describe some different 
expression systems for generation of HCV 
structural proteins.        
HCV vaccines  
     Up to now, there is not any vaccine for 
prevention of HCV infections, because of the high 
levels of strain variations and low efficiency of 
virus replication in appropriate cell cultures [3]. 
However, development of an effective vaccine 
 




has likely critical role in the control of HCV 
infections [2]. There are two main approaches for 
HCV vaccine development, including 
prophylactic and therapeutic vaccines for clinical 
use [9]. Structural proteins were known as the 
main vaccine candidates [1]. Indeed, the 
recombinant HCV core protein could be presented 
as a major vaccine candidate [5]. Generally, HCV 
vaccines are further designed as DNA-, peptide- 
and recombinant proteins which are currently 
underway in phase I/ II human clinical trials [9]. 
Currently, the primary step to develop an HCV 
vaccine was conducted toward the production of a 
recombinant protein as a subunit vaccine [9]. 
Thus, the use of different expression systems and 
the comparison of their efficiency are a special 
interest for researchers. Different heterologous 
systems have been applied to produce the 
recombinant HCV core and E1, E2 proteins such 
as Escherichia coli, yeast, insect cells, and 
mammalian cells [5] which are discussed as 
follows. The studies showed that some 
recombinant proteins are enough to induce 
immune response but others require adjuvant 
therapy [8]. For example, the combination of core 
protein with hsp90 as an adjuvant elicited high 
levels of total IgG and IgG2a immune responses 
[10, 12]. Also, the studies indicated that core+1 
formulation with various adjuvants may induce 
different profiles of immune responses (Th1 or 
Th2) [11].  
Escherichia coli 
     Different E.coli strains such as BL21 (DE3), 
K12, M15 and transcriptional control systems 
were being used to produce high levels of the 
proteins [13]. The recombinant HCV core 
proteins were efficiently expressed in E.coli as 
various fusion forms carrying the His-tag, the 
maltose binding protein (MBP) and glutathione S-
transferase (GST). Generally, bacterial expression 
systems offer higher yield at significantly lower 
cost compared to other expression systems [14, 
27, 28]. The authors showed that during viral 
morphogenesis, HCV core protein is cleaved by 
cellular signal peptidase into the truncated core 
proteins of 191 and 173 with molecular weights 
of 21 and 19 kDa, respectively [20, 21]. 
It has been shown that E.coli BL21 (DE3) plysS 
strains were used for production of the 
recombinant core protein using IPTG inducer. 
This system was able to generate ~ 25 ± 1 mg/l of 
the purified core protein. However, the formation 
of inclusion bodies (IB) has been considered as 
obstacles for development of the mature HCV 
core protein in E.coli. Therefore, many 
investigators have developed the truncated core 
protein in E. coli or its expression in other hosts 
[15]. In other studies, E. coli BL21 was applied as 
the recombinant expression system that was 
induced by arabinose. This system was able to 
achieve yields around 2.5 or 3.5 mg/l of the 
purified core protein (HCV core 173) [13, 16]. 
The typical yields of purified core protein from a 
one liter E. coli BL21 (DE3) bacterial culture 
using IPTG inducer were 10 and 5 mg for HCV 
core 124 and HCV core 179, respectively [71]. In 
addition, the expression of core protein as linked 
to GST using E. coli BL21 (DE3) cells was 
directed by adding IPTG. This simple procedure 
for purification of the GST-core (l-123) fusion 
protein usually resulted in yields of 50-100 mg 
protein/liter of culture medium [14]. Recombinant 
core proteins (r-core) were able to detect anti-core 
antibodies in HCV positive serum samples.  HCV 
core was able to elicit a broad range of antibody 
depending on the immunogen conformation [13, 
12]. In other report, the rate of expressed E1, E2, 
and E1E2 proteins using IPTG inducer were about 
30, 50, and 60%, respectively. Both purified E1E2 
chimeric proteins and E2 protein could interact 
with a putative cellular receptor CD81, while 
purified E1 protein could not interact with CD81. 
The sera of rabbit immunized with the E1E2 
inhibited the binding of E2 protein to the major 
extracellular loop of human CD81 and reacted 
with both E1 and E2 proteins, respectively. Anti-
E1 and E2 antibodies could be generated 
simultaneously in the rabbit immunized with the 
E1E2, and the titers of antibodies were 63 or 56% 
higher than the titers induced by E1 or E2, 
respectively [22]. Our group also showed that the 
BL21 strain was more potent than Rosetta strain 
for generation of HCV core protein in pET28a 
expression system. On the other hand, M15 strain 
was suitable for expression of coreE1E2 in pQE-
30 bacterial system.  
Herein, the purification of HCV core and core-
E1E2 proteins was performed using the reverse 
staining procedure without the need of any 
chromatography columns [29].  
 





    The baculovirus-insect cell expression system 
has two features which make it suitable for HCV 
protein expression: a) the eukaryotic insect cells 
possess several co- or post-translational 
modifications, including fatty acid acetylation and 
glycosylation, similar to mammalian cells; b) 
unlike many mammalian cell expression systems, 
the baculovirus expression system produces high 
levels of heterologous proteins [3]. In order to 
expression of HCV structural proteins, Sf9 insect 
cells (Spodoptera frugiperda) were co-transfected 
with wild type baculovirus [23].  Furthermore, the 
production of HCV-like particles in insect cells 
was performed using a recombinant baculovirus 
containing the cDNA of the HCV core E1E2 
structural proteins [24]. 
Yeasts 
    Pichia pastoris strain as an efficient yeast 
system was used for HCV protein expression. It 
has been reported that HCV proteins generated in 
Pichia pastoris induce strong immune responses in 
animal models.  
This system is also faster, easier, and less 
expensive than expression systems derived from 
higher eukaryotes including insects and 
mammalian cells and generally produces higher 
levels of protein expression. But some authors 
reported that it was difficult to express HCV 
envelope proteins by Pichia pastoris [1]. In one 
study, low levels of protein expression (e.g., 
HCcAg.120 or HCcAg.176) were observed in the 
recombinant Pichia pastoris cells [25]. In addition, 
Pichia pastoris strain GS115 was used for 
expression of core E1E2 protein by methanol 
inducer [1]. In other study, Pichia pastoris strain 
SMD1168 was used for expression of E1E2 
 proteins under induction by methanol. The yeast 
could produce high levels of the recombinant HCV 
E1E2 protein. The final yield of recombinant E1E2 
protein was estimated at 35 mg/l. The recombinant 
HCV E1E2 protein showed complex glycosylation 
and could bind to CD81, the putative HCV 
receptor. The purified protein could efficiently 
induce anti-E1E2 antibodies in rabbits, which were 
able to neutralize two kinds of HCV pseudotype 
particles derived from HCV genotype 1a and 1b, as 
well as HCV virions derived from HCV genotype 
2a (2). 
Mammalian cells 
For over two decades, different mammalian cell 
lines have been developed as a source of 
commercial therapeutic proteins for clinical 
applications, because of their ability for proper 
protein folding, assembly and post-translational 
modification (e.g., the correct glycosylation 
pattern) [30, 31]. However, high costs of 
production and potential safety concerns remained 
a challenge for these systems. In one report, a 
recombinant CHO cell line expressing HCV E2 
was established as a secretory form. The 
recombinant E2 protein was produced at a high 
level (~ 7 mg/l) and purified using simple 
immunoaffinity chromatography up to 4 mg/l. This 
protein could frequently recognized by E2-specific 
antibodies in patient sera [26]. 
 
CONCLUSION 
According to the challenges of hepatitis C 
treatment, it is important to develop a vaccine to 
prevent HCV infection. The data showed that the 
recombinant proteins-based vaccine candidates 
induce an immune response to a limited number of 
viral epitopes which are expressed in bacteria, 
insect, yeast or mammalian cells. However, the 
yield and safety of the recombinant proteins are 
two important issues for the use of different 
expression systems.   
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